Forte Biosciences, Inc. Common Stock
FBRX
Closed
$41.76
Closed
-(-)
At close
Get professional financial guidance
Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply
About
Forte Biosciences, Inc. is a biopharmaceutical company, which engages in the provision of dermatology products and services. The company is headquartered in Dallas, Texas and currently employs 19 full-time employees. The company went IPO on 2017-04-13. The company is advancing clinical development of FB102 into patient-based trials for celiac disease and non-segmental vitiligo. The firm's FB102 program focuses on addressing key pathways implicated in these indications with a CD122 antagonist. CD122 is a subunit of IL-2/IL-15 receptors which are key regulators of NK cells and certain T cell subsets. FB102 has potentially other autoimmune and autoimmune-related applications including vitiligo, alopecia areata, and type 1 diabetes (T1D). Its subsidiaries include Forte Subsidiary, Inc. and Forte Biosciences Australia Proprietary Limited.
Key stats
Open
$37.52
Volume
4.87M
Market cap
$751.57M
Prev. close
$36.70
Impl / hst vl
-
Open interest
$0.00
$36.27
Day’s Range
$44.86
$15.51
52W Range
$37.58
Valuation
27
Valuation score
Overvalued
P/E
-
P/S
-
P/B
17.79
Current ratio
2.75
Debt / Equity
-1.38
ROE
-106.16%
Gross margin
-
Income growth
-10.70%
FCF growth
14.22
Analysts estimates
Consensus rating
Buy
The average rating from top 7 analysts indicates that stock is expected to perform in line with the market
Str. Sell
Sell
Hold
Buy
Str. Buy
Avg. price target
$65.03
The top 6 analysts forecasts that 12-month price may increase by 55.71%, with a low of $54.54 and a high of $78.75
$54.54
Low
$65.03
Avg
$78.75
High
Current price
Earnings
Q1 ‘26 revenue
$0.00
Q1 ‘26 net income
-$22.14M
Revenue
Net income
Previous EPS
-$1.24
Estimate EPS
-$1.05
Actual EPS
Estimate EPS
Explore the Healthcare sector
Get professional financial guidance
Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply